top of page

TB500 10MG

$185.00Price
Excluding Sales Tax
Short thymosin‑β4 motif linked to actin binding, cell migration and angiogenesis. Potential benefits include support for soft‑tissue repair and reduced inflammation in ocular/dermal models. Composition isn’t standardized across suppliers; human clinical data are minimal.
Quantity

  • TB-500 – Research & Chemical Profile

    Description

    TB‑500 (Thymosin β4 Fragment 17–23) is a research name commonly used for a short peptide fragment derived from thymosin β4 (Tβ4), a 43‑amino‑acid actin‑binding protein involved in cell migration and tissue repair. The most frequently referenced TB‑500 form corresponds to the Tβ4 residues 17–23 sequence, often with N‑terminal acetylation. This fragment lies within the Tβ4 actin‑binding region and has been studied for pro‑migratory, pro‑angiogenic, and anti‑inflammatory actions in preclinical models.

     

    Chemical Structure / Identifiers

    Property

    Detail

    Common Name

    TB‑500; Tβ4 17–23 fragment

    Parent Protein

    Thymosin β4 (TMSB4X), 43 aa

    Parent Sequence (human Tβ4)

    SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

    TB‑500 Fragment Sequence

    Leu‑Lys‑Lys‑Thr‑Glu‑Thr‑Gln (LKKTETQ); frequently N‑acetylated at the N‑terminus

    Standardization Note

    TB‑500 is a research nickname; exact sequence/termini may vary by source or salt form

    Selected Registry/DB

    NCATS GSRS lists TB‑500 as N‑Acetyl‑Leu‑Lys‑Lys‑Thr‑Glu‑Thr‑Gln (Tβ4 17–23)

     

    Primary Research Focus

    • Tissue repair and regeneration: enhances cell migration and wound closure; promotes angiogenesis in preclinical models.
    • Actin dynamics: fragment maps to the actin‑binding motif of Tβ4, supporting cytoskeletal remodeling during repair.
    • Anti‑inflammatory activity: reductions in pro‑inflammatory signaling reported in ocular and mucosal injury models.
    • Cardiovascular/ischemia models (parent Tβ4): parent protein shown to aid myocardial repair and endothelial function; fragment investigated as a minimal active domain.

     

    Safety / Limitations

    • Research Use Only; not approved for medical use. Human clinical data for TB‑500 are limited.
    • “TB‑500” is not a single standardized entity; sequences and terminal modifications may differ by supplier.
    • Quality and identity can vary across sources; verify sequence/analysis certificates for any study material.
    • Some sports anti‑doping bodies consider Tβ4/TB‑500 prohibited; consult current regulations for research in athletics contexts.

     

    Key Publications / References

    NCATS GSRS substance record: TB‑500 (N‑Acetyl‑Leu‑Lys‑Lys‑Thr‑Glu‑Thr‑Gln; Tβ4 17–23). https://gsrs.ncats.nih.gov/ginas/app/ui/substances/e850a4ce-7777-4d25-ae69-ab7174c798a4

    PubChem Compound Summary: Thymosin β4 (also listed as timbetasin). https://pubchem.ncbi.nlm.nih.gov/compound/Thymosin-beta4

    Wikipedia (overview, sequence, actin binding, INN timbetasin). https://en.wikipedia.org/wiki/Thymosin_beta-4

    Review (2021): Progress on the Function and Application of Thymosin β4. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/

    Ocular/corneal wound healing with Tβ4: Sosne et al., review. https://europepmc.org/article/med/20536468

    Palatal wound healing study in rats with Tβ4: Zhu et al., 2014. https://www.spandidos-publications.com/10.3892/ijmm.2014.1832

bottom of page